191 related articles for article (PubMed ID: 26187373)
1. Therapeutic drug monitoring of voriconazole in Japanese patients: analysis based on clinical practice data.
Matsumoto K; Abematsu K; Shigemi A; Kanazawa N; Watanabe E; Yokoyama Y; Ikawa K; Morikawa N; Takeda Y
J Chemother; 2016 Jun; 28(3):198-202. PubMed ID: 26187373
[TBL] [Abstract][Full Text] [Related]
2. Voriconazole trough concentration and hepatotoxicity in patients with low serum albumin
.
Hirata A; Noto K; Ota R; Yokoyama S; Hosomi K; Takada M; Matsuoka H
Int J Clin Pharmacol Ther; 2019 Mar; 57(3):135-143. PubMed ID: 30686290
[TBL] [Abstract][Full Text] [Related]
3. Significance of monitoring plasma concentration of voriconazole in a patient with liver failure: A case report.
Liu X; Su H; Tong J; Chen J; Yang H; Xiao L; Hu J; Zhang L
Medicine (Baltimore); 2017 Oct; 96(42):e8039. PubMed ID: 29049191
[TBL] [Abstract][Full Text] [Related]
4. Development of a therapeutic drug-monitoring algorithm for outpatients receiving voriconazole: A multicentre retrospective study.
Kato H; Umemura T; Hagihara M; Shiota A; Asai N; Hamada Y; Mikamo H; Iwamoto T
Br J Clin Pharmacol; 2024 May; 90(5):1222-1230. PubMed ID: 38320604
[TBL] [Abstract][Full Text] [Related]
5. Clinical Practice Guideline for the Therapeutic Drug Monitoring of Voriconazole in Non-Asian and Asian Adult Patients: Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.
Takesue Y; Hanai Y; Oda K; Hamada Y; Ueda T; Mayumi T; Matsumoto K; Fujii S; Takahashi Y; Miyazaki Y; Kimura T;
Clin Ther; 2022 Dec; 44(12):1604-1623. PubMed ID: 36424314
[TBL] [Abstract][Full Text] [Related]
6. Effect of Therapeutic Drug Monitoring and Cytochrome P450 2C19 Genotyping on Clinical Outcomes of Voriconazole: A Systematic Review.
Lee J; Ng P; Hamandi B; Husain S; Lefebvre MJ; Battistella M
Ann Pharmacother; 2021 Apr; 55(4):509-529. PubMed ID: 32772568
[TBL] [Abstract][Full Text] [Related]
7. [Clinical implication of therapeutic drug monitoring on voriconazole from the aspect of the analysis for CYP2C19 gene].
Kimura M; Yamagishi Y; Kawasumi N; Hagihara M; Hasegawa T; Mikamo H
Jpn J Antibiot; 2010 Jun; 63(3):255-64. PubMed ID: 20976881
[TBL] [Abstract][Full Text] [Related]
8. Effects of antifungal stewardship using therapeutic drug monitoring in voriconazole therapy on the prevention and control of hepatotoxicity and visual symptoms: A multicentre study conducted in Japan.
Hamada Y; Ueda T; Miyazaki Y; Nakajima K; Fukunaga K; Miyazaki T; Nakada-Motokawa N; Nagao M; Kawamura H; Shigemi A; Ebihara F; Kimura T; Ikegame K; Uchino M; Ikeuchi H; Takesue Y
Mycoses; 2020 Aug; 63(8):779-786. PubMed ID: 32510723
[TBL] [Abstract][Full Text] [Related]
9. Association of sustained high plasma trough concentration of voriconazole with the incidence of hepatotoxicity.
Suzuki Y; Tokimatsu I; Sato Y; Kawasaki K; Sato Y; Goto T; Hashinaga K; Itoh H; Hiramatsu K; Kadota J
Clin Chim Acta; 2013 Sep; 424():119-22. PubMed ID: 23747486
[TBL] [Abstract][Full Text] [Related]
10. Voriconazole therapeutic drug monitoring in critically ill patients improves efficacy and safety of antifungal therapy.
Li H; Li M; Yan J; Gao L; Zhou L; Wang Y; Li Q; Wang J; Chen T; Wang T; Zheng J; Qiang W; Zhang Y; Shi Q
Basic Clin Pharmacol Toxicol; 2020 Dec; 127(6):495-504. PubMed ID: 32639669
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic administration of voriconazole with two different doses for invasive fungal infection in children and adolescents with acute myeloid leukemia.
Sano H; Kobayashi R; Hori D; Kishimoto K; Suzuki D; Yasuda K; Kobayashi K
J Microbiol Immunol Infect; 2018 Apr; 51(2):260-266. PubMed ID: 27329132
[TBL] [Abstract][Full Text] [Related]
12. An Optimized Voriconazole Dosing Strategy to Achieve Therapeutic Serum Concentrations in Children Younger than 2 Years Old.
Zembles TN; Thompson NE; Havens PL; Kaufman BA; Huppler AR
Pharmacotherapy; 2016 Oct; 36(10):1102-1108. PubMed ID: 27548272
[TBL] [Abstract][Full Text] [Related]
13. Optimal timing for therapeutic drug monitoring of voriconazole to prevent adverse effects in Japanese patients.
Hanai Y; Ueda T; Hamada Y; Oda K; Takahashi Y; Nakajima K; Miyazaki Y; Kiriyama M; Uekusa S; Matsuo K; Matsumoto K; Kimura T; Takesue Y
Mycoses; 2023 Dec; 66(12):1035-1044. PubMed ID: 37584173
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic drug monitoring of voriconazole helps to decrease the percentage of patients with off-target trough serum levels.
Guinea J; Escribano P; Marcos-Zambrano LJ; Peláez T; Kestler M; Muñoz P; Vena A; López-Fabal F; Bouza E
Med Mycol; 2016 May; 54(4):353-60. PubMed ID: 26739190
[TBL] [Abstract][Full Text] [Related]
15. Correlation of CYP2C19 genotype with plasma voriconazole exposure in South-western Chinese Han patients with invasive fungal infections.
Miao Q; Tang JT; van Gelder T; Li YM; Bai YJ; Zou YG; Wang LL; Shi YY
Medicine (Baltimore); 2019 Jan; 98(3):e14137. PubMed ID: 30653146
[TBL] [Abstract][Full Text] [Related]
16. Voriconazole therapeutic drug monitoring: Factors associated with supratherapeutic and subtherapeutic voriconazole concentrations.
You H; Dong Y; Zou Y; Zhang T; Lei J; Chen L; Wang X; Dong Y; Wang T
Int J Clin Pharmacol Ther; 2018 May; 56(5):239-246. PubMed ID: 29393850
[TBL] [Abstract][Full Text] [Related]
17. Voriconazole therapeutic drug monitoring: results of a prematurely discontinued randomized multicenter trial.
Neofytos D; Ostrander D; Shoham S; Laverdiere M; Hiemenz J; Nguyen H; Clarke W; Brass L; Lu N; Marr KA
Transpl Infect Dis; 2015 Dec; 17(6):831-7. PubMed ID: 26346408
[TBL] [Abstract][Full Text] [Related]
18. Determination of plasma unbound fraction of voriconazole in patients treated with a prophylactic or a curative treatment.
Florent A; Gandia P; Seraissol P; Chatelut E; Houin G
Ther Drug Monit; 2014 Dec; 36(6):752-8. PubMed ID: 24819971
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic drug monitoring and safety of voriconazole in elderly patients.
Cheng L; Xiang R; Liu F; Li Y; Chen H; Yao P; Sun F; Xia P
Int Immunopharmacol; 2020 Jan; 78():106078. PubMed ID: 31830620
[TBL] [Abstract][Full Text] [Related]
20. Enhancing the identification of voriconazole-associated hepatotoxicity by targeted metabolomics.
Chiang YH; Cheng CN; Chuang PJ; Chen YC; Chen YJ; Kuo CH; Lin SW; Chang LC
Int J Antimicrob Agents; 2024 Jan; 63(1):107028. PubMed ID: 37931850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
